The FDA has approved a novel oral medication for the prevention of chronic migraines. Clinical trials showed a significant reduction in monthly migraine days for patients.
The drug targets CGRP receptors and offers an alternative for those who cannot tolerate injectable therapies. Insurance coverage details are being finalized.
